INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 140 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2017. The put-call ratio across all filers is 1.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,793,000 | -62.9% | 38,536 | -54.5% | 0.01% | -60.9% |
Q2 2022 | $4,836,000 | -25.2% | 84,720 | -19.9% | 0.02% | +9.5% |
Q1 2022 | $6,469,000 | +1947.2% | 105,728 | +428.6% | 0.02% | +2000.0% |
Q3 2017 | $316,000 | +96.3% | 20,000 | +53.8% | 0.00% | 0.0% |
Q2 2017 | $161,000 | -20.3% | 13,000 | +150.0% | 0.00% | 0.0% |
Q2 2016 | $202,000 | -24.6% | 5,200 | -22.4% | 0.00% | 0.0% |
Q3 2015 | $268,000 | -74.2% | 6,700 | -79.4% | 0.00% | -80.0% |
Q2 2015 | $1,037,000 | -73.6% | 32,450 | -80.3% | 0.01% | -72.2% |
Q1 2015 | $3,935,000 | – | 164,797 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |